Current state of the problem of selecting patients with benign prostatic hyperplasia for surgical treatment
https://doi.org/10.34215/1609-1175-2025-4-30-37
Abstract
Selection of candidates with benign prostatic hyperplasia (BPH) for surgery remains an unsolved clinical task due to the lack of uniform, reproducible criteria. This impedes prediction of outcomes with comparable follow-up effectiveness of different surgical methods. Evidence synthesis indicates that subjective symptom scales, morphological descriptors, and functional parameters each have limited discriminative value when used in isolation. A more accurate, personalized decision-making framework may emerge from integrating analytical urodynamics with neurophysiological insights into detrusor–sphincter coordination, thereby improving risk stratification and surgical indication setting.
About the Authors
V. V. Danilov
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
D. A. Radko
Pacific State Medical University
Russian Federation
Russian Federation
Dmitrii A. Radko, graduate student of the Institute of Surgery
2 Ostryakova ave., Vladivostok, 690002, Russia
tel.: +7 (914) 799-75-19
References
1. Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 32644346.
2. Mirone V, Imbimbo C, Longo N, Fusco F. The correlation between symptoms and bladder outlet obstruction parameters in benign prostatic hyperplasia patients. European Urology. 2007;51(4):1019–25. doi: 10.1016/j.eururo.2007.01.047
3. World Health Organization. World Health Statistics 2021: Monitoring health for the SDGs. Geneva: WHO; 2021. p. 45–8.
4. United Nations. World Population Ageing 2020. 2020. ST/ESA/SER.A/451. doi: 10.18356/9789210051941
5. Huang LK, Chang YH, Shao IH, Lee TL, Hsieh ML. Clinical Outcome of Immediate Transurethral Surgery for Benign Prostate Obstruction Patients with Acute Urinary Retention: More Radical Resection Resulted in Better Voiding Function. J Clin Med. 2019 Aug 22;8(9):1278. doi: 10.3390/jcm8091278.
6. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. The Journal of Urology. 1984;132(3):474–9. doi: 10.1016/s0022-5347(17)49698-4
7. Jacobsen SJ, Jacobson DJ, Girman CJ. Natural history of prostatism: risk factors for acute urinary retention. The Journal of Urology. 1997;158(2):481–7. doi: 10.1016/s0022-5347(01)64564-3
8. Ye L, Zhu Y, Lu J. Global burden and trends of benign prostatic hyperplasia: a population-based study from 1990 to 2019. BMC Urology. 2024;24(1):52. doi: 10.1186/s12894-024-01582-w
9. Chen X, Zhang Y, Wang J. The prevalence and risk factors of benign prostatic hyperplasia: a cross-sectional study. Scientific Reports. 2025;15(1):1157. doi: 10.1038/s41598-025-90229-3
10. Sekido N, Omae K, Haga N, Kubota Y, Saito M, Sakakibara R, Yoshida M, Mitsui T, Masumori N, Takahashi S. Impact of Lower Urinary Tract Symptoms on Daily Life in Individuals With Co-Existence Overactive and Underactive Bladder, Overactive Bladder, and Underactive Bladder. Low Urin Tract Symptoms. 2025 Sep;17(5):e70026. doi: 10.1111/luts.70026.
11. Boyarsky ST, Jones GW, Paulson DF, Prout GR Jr. New guidelines for investigation of benign prostatic hypertrophy (FDA Workshop, 1976). Urology. 1977;10(2):186–9. doi: 10.1016/0090-4295(77)90099-8
12. Madsen PO, Iversen PA. A point system for selecting operative candidates. In: Benign Prostatic Hyperplasia: NIH Conference. 1982. p. 763–5.
13. Barry MJ, Fowler FJ Jr, O'Leary MP. Measuring disease-specific health status in men with benign prostatic hyperplasia. Medical Care. 1995;33(4 Suppl):AS145–55. PMID: 7723455.
14. Hansen BJ, Dahlstrand C, Hjälmås K, Pettersson S, Ströberg P. The prevalence and bothersomeness of lower urinary tract symptoms in men 45-65 years old. British Journal of Urology. 1998;81(1):36–41. doi: 10.1046/j.1464-410x.1998.00524.x
15. Gandhi J, Weissbart SJ, Kim AN, Joshi G, Kaplan SA, Khan SA. Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. Curr Urol. 2018 Oct;12(1):6-12. doi: 10.1159/000447224.
16. Cella D, Gries KS, Brucker PS, Guedea F, Hagan M, Karsh J, Korman H, Kuban DA, Mahadevan A, Monitto DC, Niewoehner J, Samsa GP, Slevin JT, Talcott JA. The patient-reported outcomes measurement information system (PROMIS) and quality of life in patients with benign prostatic hyperplasia. The Journal of Urology. 2020;203(1):164–70. doi: 10.1097/JU.0000000000000469
17. De Win G, Peters M, Pauwels J, Van Aggelpoel T, De Wachter S. The Added Value of Home-Uroflowmetry: Analyzing an Individuals’ VV-Qmax Curve and Inflection Point. The Journal of Urology. 2025. PMID: 40074155.
18. Lee H, Kim S, Park J, Choi H. Flow prediction in sound-based uroflowmetry. Scientific Reports. 2025;15:84978. doi: 10.1038/s41598-024-84978-w
19. Sánchez-Ortiz R, Morales J, García-Rojo E, Brenes F, Pérez A, Arlandis S, Castro-Díaz D. Reliability of Uroflowmetry Pattern Interpretation. Neurourology and Urodynamics. 2023;42(2):303–10. doi: 10.1002/nau.25584
20. Groutz A, Blaivas JG. The Pressure-Flow Study Revisited. Current Urology Reports. 2022;23(1):15–20. doi: 10.1007/s11934-022-01087-9
21. Dmochowski RR, Goldman HB, Nitti VW, Heesakkers JPFA, Gormley EA. Pressure-flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Current Urology Reports. 2024;25(2):105–10. doi: 10.1007/s11934-023-01193-2
22. Turner KJ, MacLennan G, Coutts E, McDonald A, Bach T, Kotsiris G, Kasyan G, De Nunzio C, Thomas D, Drake MJ, Gammie A, Abrams P, Tandogdu Z, N'Dow J. The UPSTREAM trial. BMJ. 2021;372:n165. doi: 10.1136/bmj.n165
23. Pfisterer M, Griffiths D, Schaefer W. Reproducibility of pressure– flow studies. European Urology. 2023;85(1):127–34. doi: 10.1016/j.eururo.2022.10.002
24. Kortmann BB, Floratos DL, Kiemeney LA. Urodynamic effects of alpha-blocker tamsulosin in symptomatic benign prostatic hyperplasia. British Journal of Urology. 2003;92(1):81–6. doi: 10.1046/j.1464-410x.2003.04280.x
25. Chan V, Reynolds WS. Contemporary role of urodynamics in the evaluation of male lower urinary tract symptoms. Current Urology Reports. 2024;25(4):220–5. doi: 10.1007/s11934-024-01204-w
26. Teramoto Y, Kojima Y, Takahashi N, Yokoyama O. The efficacy and safety of a novel combination therapy for male lower urinary tract symptoms. International Urology and Nephrology. 2025;57(3):665–73. doi: 10.1007/s11255-025-03620-3
27. American Urological Association. Guidelines on the Management of Benign Prostatic Hyperplasia. 2021.
28. Lopategui DM, Chughtai B, Kaplan SA. Reassessing the role of post-void residual in treatment decision-making. Urology. 2025;174:85–91. doi: 10.1016/j.urology.2024.12.015
29. Gryet IM, Vallet M, Roumiguié M, Mallet R, Robert G, Beauval JB. Residual urine before and after surgery in elderly men with BPH. Neurourology and Urodynamics. 2025;44(2):210–7. doi: 10.1002/nau.25891
30. Kwon DD, Lee JY, Kim SO, Park HJ, Kim SJ. Clinical effects of mirabegron and tamsulosin combination therapy on PVR. The World Journal of Men's Health. 2024;42(1):37–44. doi: 10.5534/wjmh.250085
31. Oelke M, Höfner K, Jonas U, Wiese B, Bachmann A. Diagnostic value of the PVR index in men with LUTS/BPH. Urologia Internationalis. 2022;108(3):250–6. doi: 10.1159/000520333
32. European Association of Urology. EAU Guidelines on Management of Non-neurogenic Male LUTS including Benign Prostatic Hyperplasia. 2024.
33. Gammie A, Kessler TM, Yamanishi T, Romero-Otero J, Ikeda Y, Gilling P. Systematic review of detrusor underactivity: clinical features and urodynamic findings. Neurourology and Urodynamics. 2023;42(4):789–98. doi: 10.1002/nau.24890
34. Kim HJ, Song W, Jeong BC, Seo HK, Lee J. Total prostate volume as a predictor of medical treatment failure in LUTS/BPH. BMC Urology. 2022;22(1):15–22. doi: 10.1186/s12894-022-00915-5
35. Cho KS, Kim J, Yoo S, Park J, Lee JY. Surgical outcomes in large prostates: is size alone a predictor of complexity? World Journal of Urology. 2023;41(4):1001–8. doi: 10.1007/s00345-023-04100-3
36. Zhou Y, Wang Y, Zhang Y, Liu Z, Chen Y. Transition zone index as predictor of obstruction in BPH patients. Neurourology and Urodynamics. 2024;43(2):225–31. doi: 10.1002/nau.25998
37. Kwon T, Jeong W, Lim JH, Kim M, Park J. Role of intravesical prostatic protrusion in BPH management. International Neurourology Journal. 2023;27(1):45–52. doi: 10.5213/inj.2340102.033
38. Chen Y, Lin H, Wang D, Li Z, Wu J. Prostatic obstruction index in predicting surgical outcome in BPH. Urology. 2025;175: 67–74. doi: 10.1016/j.urology.2024.10.009
39. Park DS, Seo TS, Kim YH, Lee JH, Moon HS. Predictive value of PSA for prostate volume in BPH. Andrology. 2022;10(5):911–8. doi: 10.1111/andr.13124
40. Gong EM, Lee JS, Cho MC, Kim HJ, Son H. PSA and risk of AUR in BPH patients. Urology. 2023;165:78–84. doi: 10.1016/j.urology.2022.11.007
41. Matsumoto K, Hori S, Takeuchi T, Ishikawa T, Fukuta F. Role of PSA in estimating prostate volume in BPH. The Journal of Urology. 2024;211(2):394–400. doi: 10.1097/JU.0000000000003492
42. Taniguchi Y, Okamoto Y, Yoshimura K, Fukasawa S. Clinical relevance of PSA density in men with LUTS. International Journal of Urology. 2025;32(1):50–6. doi: 10.1111/iju.15112
43. Shin YS, Jeong SY, Lee JH, Kim HW, Park HJ. PSA and pharmacological failure in BPH. The World Journal of Men's Health. 2023;41(2):128–36. doi: 10.5534/wjmh.230028
44. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. The New England Journal of Medicine. 2003;349(25):2387–98. doi: 10.1056/NEJMoa030656
45. Zhou Z, Yang H, Zhao Z, Liu L, Wang X. Development of a predictive model for surgical indication in BPH patients. Prostate International. 2021;9(3):123–9. doi: 10.1016/j.prnil.2021.06.003
46. Patel AR, Jones JS, Zippe CD, Malaeb BS, Kattan MW. The BPH risk stratification system: a practical guide to treatment decisions. Current Urology Reports. 2022;23(1):14–21. doi: 10.1007/s11934-021-01066-w
47. Lee JY, Kim H, Moon YJ, Park J, Cho MC. Machine learning prediction model for surgery in BPH patients. World Journal of Urology. 2023;41(7):1789–97. doi: 10.1007/s00345-023-04144-5
48. Gacci M, Serni S, Rizzo M, Carini M, Saleh O, Sebastianelli A, Spatafora P, Vignozzi L, De Nunzio C, McVary KT, Kaplan SA, Gravas S, Novara G. Detrusor underactivity and surgical outcomes in BPH patients. Neurourology and Urodynamics. 2024;43(2):419–25. doi: 10.1002/nau.25191
49. Chen Y, Wu M, Liu Z, Zhang W, Wang J. Postvoid residual urine index: a novel predictor of treatment failure in BPH patients. Urologia Internationalis. 2022;106(2):158–64. doi: 10.1159/000521402
50. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male LUTS. European Urology. 2023;84(1):58–75. doi: 10.1016/j.eururo.2022.11.012
Review
For citations:
Danilov V.V., Radko D.A. Current state of the problem of selecting patients with benign prostatic hyperplasia for surgical treatment. Pacific Medical Journal. 2025;(4):30-37. (In Russ.) https://doi.org/10.34215/1609-1175-2025-4-30-37
Views:
222
JATS XML
Email this article 